Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) - Global Forecast to 2026
The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled & trained professionals may challenge market growth to a certain extent.
“SELEX is the largest end-user segment in the aptamers market in 2020”
Based on technology, the aptamers market is segmented into SELEX and other technologies. The SELEX technology segment dominated the market in 2020. The segment accounts for a large share of the aptamers market as SELEX is one of the most widely used technologies. The other technologies segment is expected to register the highest CAGR during the forecast period due to the increasing focus on developing technologies for aptamer selection.
“Diagnostic segment is anticipated to witness the fastest growth during the forecast period.”
Based on the application, the aptamers market is segmented into therapeutics development, research & development, diagnostics, and other applications. In 2020, the therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. The diagnostic segment is projected to grow at the highest CAGR due to the increasing prevalence of chronic diseases and the development of new diagnostic kits to detect cancer and other diseases.
“Asia Pacific region is anticipated to witness the fastest growth during the forecast period.”
The aptamers market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to record the highest CAGR during the forecast period. This is attributed to the rising R&D activities on aptamers, the development of aptamer-based products, and the rising focus on drug discovery and development.
The break-down of primary participants is as mentioned below:
Research Coverage:
The report analyzes the aptamers market and aims at estimating the market size and future growth potential of various market segments, based on type, technology, application, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
“SELEX is the largest end-user segment in the aptamers market in 2020”
Based on technology, the aptamers market is segmented into SELEX and other technologies. The SELEX technology segment dominated the market in 2020. The segment accounts for a large share of the aptamers market as SELEX is one of the most widely used technologies. The other technologies segment is expected to register the highest CAGR during the forecast period due to the increasing focus on developing technologies for aptamer selection.
“Diagnostic segment is anticipated to witness the fastest growth during the forecast period.”
Based on the application, the aptamers market is segmented into therapeutics development, research & development, diagnostics, and other applications. In 2020, the therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. The diagnostic segment is projected to grow at the highest CAGR due to the increasing prevalence of chronic diseases and the development of new diagnostic kits to detect cancer and other diseases.
“Asia Pacific region is anticipated to witness the fastest growth during the forecast period.”
The aptamers market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to record the highest CAGR during the forecast period. This is attributed to the rising R&D activities on aptamers, the development of aptamer-based products, and the rising focus on drug discovery and development.
The break-down of primary participants is as mentioned below:
- By Company Type - Tier 1: 35%, Tier 2: 40%, and Tier 3: 25%
- By Designation - C-level: 45%, Director-level: 30%, and Others: 25%
- By Region - North America: 40%, Europe: 25%, Asia Pacific: 20%, Latin America: 10%, and the Middle East & Africa: 5%
Research Coverage:
The report analyzes the aptamers market and aims at estimating the market size and future growth potential of various market segments, based on type, technology, application, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the aptamers market. The report analyzes this market by type, technology, application, end user and region
- Market Development: Comprehensive information on the lucrative emerging markets, by type, technology, application, end user and region
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the aptamers market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the aptamers market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 APTAMERS MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATION
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 APTAMERS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF APTAMERS IN THE MARKET
FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 6 APTAMERS MARKET: CAGR PROJECTIONS, 2021–2026
FIGURE 7 APTAMERS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 10 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 11 APTAMERS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 APTAMERS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 13 APTAMERS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 14 APTAMERS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT: APTAMERS MARKET
4 PREMIUM INSIGHTS
4.1 APTAMERS MARKET OVERVIEW
FIGURE 16 INCREASING INVESTMENTS IN PHARMACEUTICAL R&D
TO SUPPORT MARKET GROWTH
4.2 NORTH AMERICA: APTAMERS MARKET SHARE, BY TYPE & COUNTRY (2020)
FIGURE 17 DNA APTAMERS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN APTAMERS MARKET IN 2020
4.3 APTAMERS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 18 XNA APTAMERS SEGMENT WILL DOMINATE THE MARKET IN 2026
4.4 APTAMERS MARKET SHARE, BY END USER, 2020
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020
4.5 APTAMERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH FROM 2021 TO 2026
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 APTAMERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 APTAMERS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising number of clinical trials to develop aptamer-based therapeutics
TABLE 2 LIST OF APTAMERS/APTAMER-BASED THERAPEUTICS IN PIPELINE
5.2.1.2 Rising awareness of the advantages of aptamers over antibodies
5.2.1.3 Investments in pharmaceutical R&D
FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
TABLE 3 R&D SPENDING OF PROMINENT PHARMACEUTICAL COMPANIES IN 2019 & 2020 (USD BILLION
5.2.1.4 Rising prevalence of chronic and rare diseases
FIGURE 23 GLOBAL PREVALENCE OF CANCER, BY TYPE
5.2.2 RESTRAINTS
5.2.2.1 Low market acceptance as compared to antibodies
5.2.3 OPPORTUNITIES
5.2.3.1 Growth in the venture capital funding for research on aptamers
5.2.3.2 Growing collaborations with research institutes and pharmaceutical companies
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled & trained professionals
5.3 IMPACT OF COVID-19 OUTBREAK ON THE APTAMERS MARKET
FIGURE 24 APTAMERS MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021 (USD MILLION)
5.4 PIPELINE ANALYSIS
TABLE 4 THERAPEUTIC PIPELINE OF APTAMERS IN VARIOUS PHASES OF DRUG DEVELOPMENT
5.5 TECHNOLOGY ANALYSIS
5.6 PORTERS FIVE FORCES ANALYSIS
TABLE 5 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 THREAT OF SUBSTITUTES
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 ECOSYSTEM ANALYSIS
FIGURE 25 APTAMERS MARKET: ECOSYSTEM ANALYSIS
5.8 VALUE CHAIN ANALYSIS
FIGURE 26 VALUE CHAIN: APTAMERS MARKET
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS
FIGURE 27 PATENT PUBLICATION TRENDS: 2010–2021
5.9.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES)
FOR APTAMER PATENTS
TABLE 6 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR APTAMER PATENTS
FIGURE 28 JURISDICTION ANALYSIS FOR THE US (2014–2021)
6 APTAMERS MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 7 APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.2 DNA APTAMERS
6.2.1 INCREASING USE OF DNA APTAMERS AND THEIR WIDE AVAILABILITY BOOSTS SEGMENT GROWTH
TABLE 8 DNA APTAMERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 9 NORTH AMERICA: DNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 10 EUROPE: DNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 11 ASIA PACIFIC: DNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 XNA APTAMERS
6.3.1 FOCUS ON DEVELOPING NEXT-GENERATION APTAMERS FOR SPECIFIC TARGETS TO BOOST SEGMENT GROWTH
TABLE 12 XNA APTAMERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 13 NORTH AMERICA: XNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 EUROPE: XNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 15 ASIA PACIFIC: XNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4 RNA APTAMERS
6.4.1 INCREASING RESEARCH ACTIVITIES FOR THE USE OF RNA APTAMERS BOOSTS SEGMENT GROWTH
TABLE 16 RNA APTAMERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 17 NORTH AMERICA: RNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 18 EUROPE: RNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 19 ASIA PACIFIC: RNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 APTAMERS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 20 APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
7.2 SELEX
7.2.1 SELEX IS THE MOST WIDELY USED TECHNOLOGY FOR APTAMERS SELECTION
TABLE 21 SELEX TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 22 NORTH AMERICA: SELEX TECHNOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 23 EUROPE: SELEX TECHNOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 24 ASIA PACIFIC: SELEX TECHNOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 OTHER TECHNOLOGIES
TABLE 25 OTHER TECHNOLOGIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 26 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 27 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 28 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 APTAMERS MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 29 APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
8.2 THERAPEUTICS DEVELOPMENT
8.2.1 PROMINENT PLAYERS OFFERING SERVICES FOR THERAPEUTICS DEVELOPMENT TO BOOST THE MARKET GROWTH
TABLE 30 APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 31 NORTH AMERICA: APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 32 EUROPE: APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 33 ASIA PACIFIC: APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 RESEARCH & DEVELOPMENT
8.3.1 INCREASING AVAILABILITY OF APTAMERS FOR ACADEMIC RESEARCH TO DRIVE MARKET GROWTH
TABLE 34 APTAMERS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 35 NORTH AMERICA: APTAMERS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 36 EUROPE: APTAMERS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 ASIA PACIFIC: APTAMERS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 DIAGNOSTICS
8.4.1 THE INCREASING PREVALENCE OF DISEASES SUCH AS CANCER AND PRODUCT LAUNCHES ARE PROJECTED TO DRIVE THE SEGMENT GROWTH
TABLE 38 APTAMERS MARKET FOR DIAGNOSTICS, BY REGION, 2019–2026 (USD MILLION)
TABLE 39 NORTH AMERICA: APTAMERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 40 EUROPE: APTAMERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 41 ASIA PACIFIC: APTAMERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 OTHER APPLICATIONS
TABLE 42 APTAMERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 43 NORTH AMERICA: APTAMERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 44 EUROPE: APTAMERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 ASIA PACIFIC: APTAMERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
9 APTAMERS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 46 APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 PROMINENT PLAYERS OFFERING SERVICES FOR DRUG DEVELOPMENT TO DRIVE MARKET GROWTH
TABLE 47 APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 EUROPE: APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 ASIA PACIFIC: APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
9.3.1 COLLABORATIVE EFFORTS AMONG COMPANIES & RESEARCH INSTITUTES WILL DRIVE THE GROWTH OF THE MARKET
TABLE 51 APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 53 EUROPE: APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 54 ASIA PACIFIC: APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.4.1 RESEARCH PARTNERSHIPS BETWEEN PHARMA PLAYERS AND CONTRACT ORGANIZATIONS DRIVE MARKET GROWTH
TABLE 55 APTAMERS MARKET FOR CROS, BY REGION, 2019–2026 (USD MILLION)
TABLE 56 NORTH AMERICA: APTAMERS MARKET FOR CROS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 57 EUROPE: APTAMERS MARKET FOR CROS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 ASIA PACIFIC: APTAMERS MARKET FOR CROS, BY COUNTRY, 2019–2026 (USD MILLION)
9.5 OTHER END USERS
TABLE 59 APTAMERS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 60 NORTH AMERICA: APTAMERS MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 61 EUROPE: APTAMERS MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 62 ASIA PACIFIC: APTAMERS MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
10 APTAMERS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: APTAMERS MARKET SNAPSHOT
TABLE 64 NORTH AMERICA: APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 68 NORTH AMERICA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 The US dominates the aptamers market
TABLE 69 US: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 70 US: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 71 US: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 72 US: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government funding promotes market growth
TABLE 73 CANADA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 74 CANADA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 75 CANADA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 76 CANADA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 77 EUROPE: APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 78 EUROPE: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 79 EUROPE: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 80 EUROPE: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 81 EUROPE: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 UK
10.3.1.1 Collaborative efforts for aptamer research and increasing investment in aptamers to drive market growth
TABLE 82 UK: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 83 UK: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 84 UK: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 85 UK: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Germany has reported a significant increase in aptamer-related research
TABLE 86 GERMANY: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 GERMANY: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 88 GERMANY: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 89 GERMANY: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rising investment in aptamer research to drive the market growth
TABLE 90 FRANCE: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 91 FRANCE: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 92 FRANCE: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 93 FRANCE: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Growth of the life science and pharmaceutical industry to expand the market in Italy
TABLE 94 ITALY: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 95 ITALY: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 96 ITALY: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 97 ITALY: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increased R&D funding in aptamer research to maximize market growth
TABLE 98 SPAIN: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 SPAIN: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 100 SPAIN: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 101 SPAIN: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 102 REST OF EUROPE: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 103 REST OF EUROPE: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 104 REST OF EUROPE: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 105 REST OF EUROPE: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: APTAMERS MARKET SNAPSHOT
TABLE 106 ASIA PACIFIC: APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 107 ASIA PACIFIC: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 ASIA PACIFIC: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 109 ASIA PACIFIC: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 110 ASIA PACIFIC: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 CHINA
TABLE 111 CHINA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 112 CHINA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 113 CHINA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 114 CHINA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Collaborative efforts by market players will propel market growth in Japan
TABLE 115 JAPAN: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 JAPAN: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 117 JAPAN: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 118 JAPAN: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Government initiatives and increased disease burden to boost the market growth
TABLE 119 INDIA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 120 INDIA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 121 INDIA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 122 INDIA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.4 ROAPAC
TABLE 123 ROAPAC: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 124 ROAPAC: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 125 ROAPAC: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 126 ROAPAC: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 INCREASE IN R&D EXPENDITURE TO SUPPORT THE MARKET GROWTH
TABLE 127 LATIN AMERICA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 128 LATIN AMERICA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 129 LATIN AMERICA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 130 LATIN AMERICA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 APTAMER RESEARCH AND INCREASING BURDEN OF CANCER TO PROMOTE MARKET GROWTH
TABLE 131 LUNG CANCER EPIDEMIOLOGY IN MIDDLE EAST COUNTRIES IN 2018
TABLE 132 MEA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 133 MEA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 134 MEA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 135 MEA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 31 APTAMERS MARKET: STRATEGIES ADOPTED
11.3 MARKET RANKING ANALYSIS
FIGURE 32 APTAMERS MARKET RANKING ANALYSIS, BY KEY PLAYER, 2020
11.4 COMPANY EVALUATION MATRIX
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 33 APTAMERS MARKET: COMPANY EVALUATION MATRIX, 2020
11.5 COMPETITIVE BENCHMARKING
11.5.1 COMPANY FOOTPRINT (10 COMPANIES)
FIGURE 34 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET
11.5.2 COMPANY PRODUCT & SERVICE FOOTPRINT (10 COMPANIES)
TABLE 136 PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET
11.5.3 COMPANY TECHNOLOGY FOOTPRINT (10 COMPANIES)
TABLE 137 TECHNOLOGY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET
11.5.4 COMPANY APPLICATION FOOTPRINT (10 COMPANIES)
TABLE 138 APPLICATION FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET
11.5.5 COMPANY END-USER FOOTPRINT (10 COMPANIES)
TABLE 139 END-USER FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET
11.6 COMPETITIVE SCENARIO AND TRENDS
11.6.1 PRODUCT & SERVICE LAUNCHES
TABLE 140 APTAMERS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2019–AUGUST 2021
11.6.2 DEALS
TABLE 141 APTAMERS MARKET: DEALS, JANUARY 2017–AUGUST 2021
12 COMPANY PROFILES
12.1 KEY COMPANIES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 APTAMER GROUP
TABLE 142 APTAMER GROUP: BUSINESS OVERVIEW
TABLE 143 APTAMER GROUP: PRODUCT/SERVICE OFFERINGS
TABLE 144 APTAMER GROUP: DEALS
12.1.2 RAPTAMER DISCOVERY GROUP
TABLE 145 RAPTAMER DISCOVERY GROUP: BUSINESS OVERVIEW
TABLE 146 RAPTAMER DISCOVERY GROUP: PRODUCT OFFERINGS
12.1.3 SOMALOGIC, INC.
TABLE 147 SOMALOGIC, INC.: BUSINESS OVERVIEW
TABLE 148 SOMALOGIC, INC.: PRODUCT OFFERINGS
TABLE 149 SOMALOGIC, INC.: PRODUCT LAUNCHES
TABLE 150 SOMALOGIC, INC.: DEALS
TABLE 151 SOMALOGIC, INC.: OTHER DEVELOPMENTS
12.1.4 APTAMER SCIENCES, INC.
TABLE 152 APTAMER SCIENCES, INC.: BUSINESS OVERVIEW
FIGURE 35 APTAMER SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 153 APTAMER SCIENCES, INC.: PRODUCT/SERVICE OFFERINGS
TABLE 154 APTAMER SCIENCES, INC.: PRODUCT APPROVALS
TABLE 155 APTAMER SCIENCES, INC.: DEALS
12.1.5 APTAGEN, LLC
TABLE 156 APTAGEN, LLC: BUSINESS OVERVIEW
TABLE 157 APTAGEN, LLC: PRODUCT/SERVICE OFFERINGS
TABLE 158 APTAGEN, LLC: DEALS
12.1.6 MARAVAI LIFESCIENCES
TABLE 159 MARAVAI LIFESCIENCES: BUSINESS OVERVIEW
FIGURE 36 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT
TABLE 160 MARAVAI LIFESCIENCES: SERVICE OFFERINGS
12.1.7 KANEKA CORPORATION
TABLE 161 KANEKA CORPORATION: BUSINESS OVERVIEW
FIGURE 37 KANEKA CORPORATION: COMPANY SNAPSHOT
TABLE 162 KANEKA CORPORATION: SERVICE OFFERINGS
12.1.8 NEOVENTURES BIOTECHNOLOGY INC.
TABLE 163 NEOVENTURES BIOTECHNOLOGY INC.: BUSINESS OVERVIEW
TABLE 164 NEOVENTURES BIOTECHNOLOGY INC.: PRODUCT/SERVICE OFFERINGS
12.1.9 APTUS BIOTECH
TABLE 165 APTUS BIOTECH: BUSINESS OVERVIEW
TABLE 166 APTUS BIOTECH: PRODUCT/SERVICE OFFERINGS
12.1.10 BASE PAIR BIOTECHNOLOGIES
TABLE 167 BASE PAIR BIOTECHNOLOGIES: BUSINESS OVERVIEW
TABLE 168 BASE PAIR BIOTECHNOLOGIES: PRODUCT/SERVICE OFFERINGS
TABLE 169 BASE PAIR BIOTECHNOLOGIES: OTHER DEVELOPMENTS
12.1.11 AMSBIO
TABLE 170 AMSBIO: BUSINESS OVERVIEW
TABLE 171 AMSBIO: PRODUCT/SERVICE OFFERINGS
12.1.12 NOVAPTECH
TABLE 172 NOVAPTECH: BUSINESS OVERVIEW
TABLE 173 NOVAPTECH: SERVICE OFFERINGS
TABLE 174 NOVAPTECH: DEALS
12.1.13 BIO-TECHNE
TABLE 175 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 38 BIO-TECHNE: COMPANY SNAPSHOT
TABLE 176 BIO-TECHNE: PRODUCT OFFERINGS
12.1.14 APTITUDE MEDICAL SYSTEMS
TABLE 177 APTITUDE MEDICAL SYSTEMS: BUSINESS OVERVIEW
TABLE 178 APTITUDE MEDICAL SYSTEMS: PRODUCT OFFERINGS
TABLE 179 APTITUDE MEDICAL SYSTEMS: DEALS
12.1.15 RAYBIOTECH, INC.
TABLE 180 RAYBIOTECH, INC.: BUSINESS OVERVIEW
TABLE 181 RAYBIOTECH, INC.: PRODUCT/SERVICE OFFERINGS
12.1.16 ALPHA DIAGNOSTIC INTERNATIONAL, INC.
TABLE 182 ALPHA DIAGNOSTIC INTERNATIONAL, INC.: BUSINESS OVERVIEW
TABLE 183 ALPHA DIAGNOSTIC INTERNATIONAL, INC.: PRODUCT OFFERINGS
12.1.17 CREATIVE BIOLABS
TABLE 184 CREATIVE BIOLABS: BUSINESS OVERVIEW
TABLE 185 CREATIVE BIOLABS: PRODUCT/SERVICE OFFERINGS
12.1.18 CREATIVE BIOGENE
TABLE 186 CREATIVE BIOGENE: BUSINESS OVERVIEW
TABLE 187 CREATIVE BIOGENE: PRODUCT/SERVICE OFFERINGS
12.1.19 VIVONICS INC.
TABLE 188 VIVONICS INC: BUSINESS OVERVIEW
TABLE 189 VIVONICS INC: PRODUCT/SERVICE OFFERINGS
12.1.20 IBA LIFESCIENCES GMBH
TABLE 190 IBA LIFESCIENCES GMBH: BUSINESS OVERVIEW
TABLE 191 IBA LIFESCIENCES GMBH: PRODUCT/SERVICE OFFERINGS
12.2 OTHER PLAYERS
12.2.1 APTABHARAT INNOVATIONS PVT. LTD
TABLE 192 APTABHARAT INNOVATIONS: COMPANY OVERVIEW
12.2.2 PROFACGEN
TABLE 193 PROFACGEN: COMPANY OVERVIEW
12.2.3 MEDIVEN
TABLE 194 MEDIVEN: COMPANY OVERVIEW
12.2.4 PURE BIOLOGICS SA
TABLE 195 PURE BIOLOGICS SA: COMPANY OVERVIEW
12.2.5 OAK BIOSCIENCES, INC.
TABLE 196 OAK BIOSCIENCES, INC.: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 APTAMERS MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATION
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 APTAMERS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF APTAMERS IN THE MARKET
FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 6 APTAMERS MARKET: CAGR PROJECTIONS, 2021–2026
FIGURE 7 APTAMERS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 10 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 11 APTAMERS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 APTAMERS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 13 APTAMERS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 14 APTAMERS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT: APTAMERS MARKET
4 PREMIUM INSIGHTS
4.1 APTAMERS MARKET OVERVIEW
FIGURE 16 INCREASING INVESTMENTS IN PHARMACEUTICAL R&D
TO SUPPORT MARKET GROWTH
4.2 NORTH AMERICA: APTAMERS MARKET SHARE, BY TYPE & COUNTRY (2020)
FIGURE 17 DNA APTAMERS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN APTAMERS MARKET IN 2020
4.3 APTAMERS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 18 XNA APTAMERS SEGMENT WILL DOMINATE THE MARKET IN 2026
4.4 APTAMERS MARKET SHARE, BY END USER, 2020
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020
4.5 APTAMERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH FROM 2021 TO 2026
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 APTAMERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 APTAMERS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising number of clinical trials to develop aptamer-based therapeutics
TABLE 2 LIST OF APTAMERS/APTAMER-BASED THERAPEUTICS IN PIPELINE
5.2.1.2 Rising awareness of the advantages of aptamers over antibodies
5.2.1.3 Investments in pharmaceutical R&D
FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
TABLE 3 R&D SPENDING OF PROMINENT PHARMACEUTICAL COMPANIES IN 2019 & 2020 (USD BILLION
5.2.1.4 Rising prevalence of chronic and rare diseases
FIGURE 23 GLOBAL PREVALENCE OF CANCER, BY TYPE
5.2.2 RESTRAINTS
5.2.2.1 Low market acceptance as compared to antibodies
5.2.3 OPPORTUNITIES
5.2.3.1 Growth in the venture capital funding for research on aptamers
5.2.3.2 Growing collaborations with research institutes and pharmaceutical companies
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled & trained professionals
5.3 IMPACT OF COVID-19 OUTBREAK ON THE APTAMERS MARKET
FIGURE 24 APTAMERS MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021 (USD MILLION)
5.4 PIPELINE ANALYSIS
TABLE 4 THERAPEUTIC PIPELINE OF APTAMERS IN VARIOUS PHASES OF DRUG DEVELOPMENT
5.5 TECHNOLOGY ANALYSIS
5.6 PORTERS FIVE FORCES ANALYSIS
TABLE 5 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 THREAT OF SUBSTITUTES
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 ECOSYSTEM ANALYSIS
FIGURE 25 APTAMERS MARKET: ECOSYSTEM ANALYSIS
5.8 VALUE CHAIN ANALYSIS
FIGURE 26 VALUE CHAIN: APTAMERS MARKET
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS
FIGURE 27 PATENT PUBLICATION TRENDS: 2010–2021
5.9.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES)
FOR APTAMER PATENTS
TABLE 6 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR APTAMER PATENTS
FIGURE 28 JURISDICTION ANALYSIS FOR THE US (2014–2021)
6 APTAMERS MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 7 APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.2 DNA APTAMERS
6.2.1 INCREASING USE OF DNA APTAMERS AND THEIR WIDE AVAILABILITY BOOSTS SEGMENT GROWTH
TABLE 8 DNA APTAMERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 9 NORTH AMERICA: DNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 10 EUROPE: DNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 11 ASIA PACIFIC: DNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 XNA APTAMERS
6.3.1 FOCUS ON DEVELOPING NEXT-GENERATION APTAMERS FOR SPECIFIC TARGETS TO BOOST SEGMENT GROWTH
TABLE 12 XNA APTAMERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 13 NORTH AMERICA: XNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 EUROPE: XNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 15 ASIA PACIFIC: XNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4 RNA APTAMERS
6.4.1 INCREASING RESEARCH ACTIVITIES FOR THE USE OF RNA APTAMERS BOOSTS SEGMENT GROWTH
TABLE 16 RNA APTAMERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 17 NORTH AMERICA: RNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 18 EUROPE: RNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 19 ASIA PACIFIC: RNA APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 APTAMERS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 20 APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
7.2 SELEX
7.2.1 SELEX IS THE MOST WIDELY USED TECHNOLOGY FOR APTAMERS SELECTION
TABLE 21 SELEX TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 22 NORTH AMERICA: SELEX TECHNOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 23 EUROPE: SELEX TECHNOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 24 ASIA PACIFIC: SELEX TECHNOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 OTHER TECHNOLOGIES
TABLE 25 OTHER TECHNOLOGIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 26 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 27 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 28 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 APTAMERS MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 29 APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
8.2 THERAPEUTICS DEVELOPMENT
8.2.1 PROMINENT PLAYERS OFFERING SERVICES FOR THERAPEUTICS DEVELOPMENT TO BOOST THE MARKET GROWTH
TABLE 30 APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 31 NORTH AMERICA: APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 32 EUROPE: APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 33 ASIA PACIFIC: APTAMERS MARKET FOR THERAPEUTICS DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 RESEARCH & DEVELOPMENT
8.3.1 INCREASING AVAILABILITY OF APTAMERS FOR ACADEMIC RESEARCH TO DRIVE MARKET GROWTH
TABLE 34 APTAMERS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 35 NORTH AMERICA: APTAMERS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 36 EUROPE: APTAMERS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 ASIA PACIFIC: APTAMERS MARKET FOR RESEARCH & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 DIAGNOSTICS
8.4.1 THE INCREASING PREVALENCE OF DISEASES SUCH AS CANCER AND PRODUCT LAUNCHES ARE PROJECTED TO DRIVE THE SEGMENT GROWTH
TABLE 38 APTAMERS MARKET FOR DIAGNOSTICS, BY REGION, 2019–2026 (USD MILLION)
TABLE 39 NORTH AMERICA: APTAMERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 40 EUROPE: APTAMERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 41 ASIA PACIFIC: APTAMERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 OTHER APPLICATIONS
TABLE 42 APTAMERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 43 NORTH AMERICA: APTAMERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 44 EUROPE: APTAMERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 ASIA PACIFIC: APTAMERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
9 APTAMERS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 46 APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 PROMINENT PLAYERS OFFERING SERVICES FOR DRUG DEVELOPMENT TO DRIVE MARKET GROWTH
TABLE 47 APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 EUROPE: APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 ASIA PACIFIC: APTAMERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
9.3.1 COLLABORATIVE EFFORTS AMONG COMPANIES & RESEARCH INSTITUTES WILL DRIVE THE GROWTH OF THE MARKET
TABLE 51 APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 53 EUROPE: APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 54 ASIA PACIFIC: APTAMERS MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.4.1 RESEARCH PARTNERSHIPS BETWEEN PHARMA PLAYERS AND CONTRACT ORGANIZATIONS DRIVE MARKET GROWTH
TABLE 55 APTAMERS MARKET FOR CROS, BY REGION, 2019–2026 (USD MILLION)
TABLE 56 NORTH AMERICA: APTAMERS MARKET FOR CROS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 57 EUROPE: APTAMERS MARKET FOR CROS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 ASIA PACIFIC: APTAMERS MARKET FOR CROS, BY COUNTRY, 2019–2026 (USD MILLION)
9.5 OTHER END USERS
TABLE 59 APTAMERS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 60 NORTH AMERICA: APTAMERS MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 61 EUROPE: APTAMERS MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 62 ASIA PACIFIC: APTAMERS MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
10 APTAMERS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: APTAMERS MARKET SNAPSHOT
TABLE 64 NORTH AMERICA: APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 68 NORTH AMERICA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 The US dominates the aptamers market
TABLE 69 US: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 70 US: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 71 US: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 72 US: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government funding promotes market growth
TABLE 73 CANADA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 74 CANADA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 75 CANADA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 76 CANADA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 77 EUROPE: APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 78 EUROPE: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 79 EUROPE: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 80 EUROPE: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 81 EUROPE: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 UK
10.3.1.1 Collaborative efforts for aptamer research and increasing investment in aptamers to drive market growth
TABLE 82 UK: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 83 UK: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 84 UK: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 85 UK: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Germany has reported a significant increase in aptamer-related research
TABLE 86 GERMANY: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 GERMANY: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 88 GERMANY: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 89 GERMANY: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rising investment in aptamer research to drive the market growth
TABLE 90 FRANCE: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 91 FRANCE: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 92 FRANCE: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 93 FRANCE: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Growth of the life science and pharmaceutical industry to expand the market in Italy
TABLE 94 ITALY: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 95 ITALY: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 96 ITALY: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 97 ITALY: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increased R&D funding in aptamer research to maximize market growth
TABLE 98 SPAIN: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 SPAIN: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 100 SPAIN: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 101 SPAIN: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 102 REST OF EUROPE: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 103 REST OF EUROPE: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 104 REST OF EUROPE: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 105 REST OF EUROPE: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: APTAMERS MARKET SNAPSHOT
TABLE 106 ASIA PACIFIC: APTAMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 107 ASIA PACIFIC: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 ASIA PACIFIC: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 109 ASIA PACIFIC: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 110 ASIA PACIFIC: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 CHINA
TABLE 111 CHINA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 112 CHINA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 113 CHINA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 114 CHINA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Collaborative efforts by market players will propel market growth in Japan
TABLE 115 JAPAN: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 JAPAN: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 117 JAPAN: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 118 JAPAN: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Government initiatives and increased disease burden to boost the market growth
TABLE 119 INDIA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 120 INDIA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 121 INDIA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 122 INDIA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.4 ROAPAC
TABLE 123 ROAPAC: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 124 ROAPAC: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 125 ROAPAC: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 126 ROAPAC: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 INCREASE IN R&D EXPENDITURE TO SUPPORT THE MARKET GROWTH
TABLE 127 LATIN AMERICA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 128 LATIN AMERICA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 129 LATIN AMERICA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 130 LATIN AMERICA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 APTAMER RESEARCH AND INCREASING BURDEN OF CANCER TO PROMOTE MARKET GROWTH
TABLE 131 LUNG CANCER EPIDEMIOLOGY IN MIDDLE EAST COUNTRIES IN 2018
TABLE 132 MEA: APTAMERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 133 MEA: APTAMERS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 134 MEA: APTAMERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 135 MEA: APTAMERS MARKET, BY END USER, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 31 APTAMERS MARKET: STRATEGIES ADOPTED
11.3 MARKET RANKING ANALYSIS
FIGURE 32 APTAMERS MARKET RANKING ANALYSIS, BY KEY PLAYER, 2020
11.4 COMPANY EVALUATION MATRIX
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 33 APTAMERS MARKET: COMPANY EVALUATION MATRIX, 2020
11.5 COMPETITIVE BENCHMARKING
11.5.1 COMPANY FOOTPRINT (10 COMPANIES)
FIGURE 34 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET
11.5.2 COMPANY PRODUCT & SERVICE FOOTPRINT (10 COMPANIES)
TABLE 136 PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET
11.5.3 COMPANY TECHNOLOGY FOOTPRINT (10 COMPANIES)
TABLE 137 TECHNOLOGY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET
11.5.4 COMPANY APPLICATION FOOTPRINT (10 COMPANIES)
TABLE 138 APPLICATION FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET
11.5.5 COMPANY END-USER FOOTPRINT (10 COMPANIES)
TABLE 139 END-USER FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE APTAMERS MARKET
11.6 COMPETITIVE SCENARIO AND TRENDS
11.6.1 PRODUCT & SERVICE LAUNCHES
TABLE 140 APTAMERS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2019–AUGUST 2021
11.6.2 DEALS
TABLE 141 APTAMERS MARKET: DEALS, JANUARY 2017–AUGUST 2021
12 COMPANY PROFILES
12.1 KEY COMPANIES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 APTAMER GROUP
TABLE 142 APTAMER GROUP: BUSINESS OVERVIEW
TABLE 143 APTAMER GROUP: PRODUCT/SERVICE OFFERINGS
TABLE 144 APTAMER GROUP: DEALS
12.1.2 RAPTAMER DISCOVERY GROUP
TABLE 145 RAPTAMER DISCOVERY GROUP: BUSINESS OVERVIEW
TABLE 146 RAPTAMER DISCOVERY GROUP: PRODUCT OFFERINGS
12.1.3 SOMALOGIC, INC.
TABLE 147 SOMALOGIC, INC.: BUSINESS OVERVIEW
TABLE 148 SOMALOGIC, INC.: PRODUCT OFFERINGS
TABLE 149 SOMALOGIC, INC.: PRODUCT LAUNCHES
TABLE 150 SOMALOGIC, INC.: DEALS
TABLE 151 SOMALOGIC, INC.: OTHER DEVELOPMENTS
12.1.4 APTAMER SCIENCES, INC.
TABLE 152 APTAMER SCIENCES, INC.: BUSINESS OVERVIEW
FIGURE 35 APTAMER SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 153 APTAMER SCIENCES, INC.: PRODUCT/SERVICE OFFERINGS
TABLE 154 APTAMER SCIENCES, INC.: PRODUCT APPROVALS
TABLE 155 APTAMER SCIENCES, INC.: DEALS
12.1.5 APTAGEN, LLC
TABLE 156 APTAGEN, LLC: BUSINESS OVERVIEW
TABLE 157 APTAGEN, LLC: PRODUCT/SERVICE OFFERINGS
TABLE 158 APTAGEN, LLC: DEALS
12.1.6 MARAVAI LIFESCIENCES
TABLE 159 MARAVAI LIFESCIENCES: BUSINESS OVERVIEW
FIGURE 36 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT
TABLE 160 MARAVAI LIFESCIENCES: SERVICE OFFERINGS
12.1.7 KANEKA CORPORATION
TABLE 161 KANEKA CORPORATION: BUSINESS OVERVIEW
FIGURE 37 KANEKA CORPORATION: COMPANY SNAPSHOT
TABLE 162 KANEKA CORPORATION: SERVICE OFFERINGS
12.1.8 NEOVENTURES BIOTECHNOLOGY INC.
TABLE 163 NEOVENTURES BIOTECHNOLOGY INC.: BUSINESS OVERVIEW
TABLE 164 NEOVENTURES BIOTECHNOLOGY INC.: PRODUCT/SERVICE OFFERINGS
12.1.9 APTUS BIOTECH
TABLE 165 APTUS BIOTECH: BUSINESS OVERVIEW
TABLE 166 APTUS BIOTECH: PRODUCT/SERVICE OFFERINGS
12.1.10 BASE PAIR BIOTECHNOLOGIES
TABLE 167 BASE PAIR BIOTECHNOLOGIES: BUSINESS OVERVIEW
TABLE 168 BASE PAIR BIOTECHNOLOGIES: PRODUCT/SERVICE OFFERINGS
TABLE 169 BASE PAIR BIOTECHNOLOGIES: OTHER DEVELOPMENTS
12.1.11 AMSBIO
TABLE 170 AMSBIO: BUSINESS OVERVIEW
TABLE 171 AMSBIO: PRODUCT/SERVICE OFFERINGS
12.1.12 NOVAPTECH
TABLE 172 NOVAPTECH: BUSINESS OVERVIEW
TABLE 173 NOVAPTECH: SERVICE OFFERINGS
TABLE 174 NOVAPTECH: DEALS
12.1.13 BIO-TECHNE
TABLE 175 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 38 BIO-TECHNE: COMPANY SNAPSHOT
TABLE 176 BIO-TECHNE: PRODUCT OFFERINGS
12.1.14 APTITUDE MEDICAL SYSTEMS
TABLE 177 APTITUDE MEDICAL SYSTEMS: BUSINESS OVERVIEW
TABLE 178 APTITUDE MEDICAL SYSTEMS: PRODUCT OFFERINGS
TABLE 179 APTITUDE MEDICAL SYSTEMS: DEALS
12.1.15 RAYBIOTECH, INC.
TABLE 180 RAYBIOTECH, INC.: BUSINESS OVERVIEW
TABLE 181 RAYBIOTECH, INC.: PRODUCT/SERVICE OFFERINGS
12.1.16 ALPHA DIAGNOSTIC INTERNATIONAL, INC.
TABLE 182 ALPHA DIAGNOSTIC INTERNATIONAL, INC.: BUSINESS OVERVIEW
TABLE 183 ALPHA DIAGNOSTIC INTERNATIONAL, INC.: PRODUCT OFFERINGS
12.1.17 CREATIVE BIOLABS
TABLE 184 CREATIVE BIOLABS: BUSINESS OVERVIEW
TABLE 185 CREATIVE BIOLABS: PRODUCT/SERVICE OFFERINGS
12.1.18 CREATIVE BIOGENE
TABLE 186 CREATIVE BIOGENE: BUSINESS OVERVIEW
TABLE 187 CREATIVE BIOGENE: PRODUCT/SERVICE OFFERINGS
12.1.19 VIVONICS INC.
TABLE 188 VIVONICS INC: BUSINESS OVERVIEW
TABLE 189 VIVONICS INC: PRODUCT/SERVICE OFFERINGS
12.1.20 IBA LIFESCIENCES GMBH
TABLE 190 IBA LIFESCIENCES GMBH: BUSINESS OVERVIEW
TABLE 191 IBA LIFESCIENCES GMBH: PRODUCT/SERVICE OFFERINGS
12.2 OTHER PLAYERS
12.2.1 APTABHARAT INNOVATIONS PVT. LTD
TABLE 192 APTABHARAT INNOVATIONS: COMPANY OVERVIEW
12.2.2 PROFACGEN
TABLE 193 PROFACGEN: COMPANY OVERVIEW
12.2.3 MEDIVEN
TABLE 194 MEDIVEN: COMPANY OVERVIEW
12.2.4 PURE BIOLOGICS SA
TABLE 195 PURE BIOLOGICS SA: COMPANY OVERVIEW
12.2.5 OAK BIOSCIENCES, INC.
TABLE 196 OAK BIOSCIENCES, INC.: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
